Cost-Effectiveness of Ranibizumab Versus Aflibercept in the Treatment of Visual Impairment Due to Diabetic Macular Edema: A UK Healthcare Perspective
ClinicoEconomics and Outcomes Research - New Zealand
doi 10.2147/ceor.s82556
Full Text
Open PDFAbstract
Available in full text
Date
May 1, 2015
Authors
Publisher
Informa UK Limited